| Current and emerging pharmacotherapies for obesity in Australia. | Obes Res Clin Pract | 2017 Sep - Oct | 28818558 |
| Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice. | Curr Diab Rep | 2017 May | 28378293 |
| An Update on Naltrexone/Bupropion Extended-Release in the Treatment of Obesity. | Expert Opin Pharmacother | 2016 Oct 4 | 27700187 |
| Stereoselective Glucuronidation of Bupropion Metabolites In Vitro and In Vivo. | Drug Metab Dispos | 2016 Apr | 26802129 |
| Drug treatment of obesity: current status and future prospects. | Eur J Intern Med | 2015 Mar | 25634851 |
| Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit. | Clin Cardiol | 2014 Nov | 25223901 |
| Effect of uremic serum and uremic toxins on drug metabolism in human microsomes. | Regul Toxicol Pharmacol | 2014 Mar | 24184159 |
| New medications for obesity management: changing the landscape of obesitytreatment. | Curr Opin Endocrinol Diabetes Obes | 2013 Oct | 23974768 |
| Acute behavioural effects of bupropion and naltrexone, alone and in combination, in non-deprived male rats presented with palatable mash. | Psychopharmacology (Berl) | 2013 Jul | 23455599 |
| Effects of amylin and bupropion/naltrexone on food intake and body weight areinteractive in rodent models. | Eur J Pharmacol | 2013 Jan 5 | 23178527 |